05:15 AM EDT, 07/26/2024 (MT Newswires) -- Calliditas Therapeutics ( CALT ) said Friday a phase 2b study of its setanaxib experimental therapy to treat patients with primary biliary cholangitis and elevated liver stiffness met its primary goal.

In the study, patients treated with setanaxib showed statistically significant improvement in Alkaline Phosphatase for both doses tested compared with placebo, the company said.

Setanaxib was generally well tolerated as the overall volume of treatment emergent adverse events was similar between active treatment and placebo, Calliditas said.

The company is conducting additional clinical trials with setanaxib and expects data from a phase 2 trial in idiopathic pulmonary fibrosis in Q4 this year or Q1 2025.

Price: 37.81, Change: -0.34, Percent Change: -0.89